Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( (DE:2TZ) ) has provided an update.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited held its second extraordinary general meeting for the 2025 financial year on 15 December 2025, convening A-share holders at its Da Ren Tang Mansion headquarters in Tianjin and S-share holders via video conference in Singapore. Chaired by board chairwoman Wang Lei, the meeting was duly quorate, with A-share voting conducted through a combination of on-site and online channels, underscoring the company’s continued use of hybrid meeting and voting arrangements to accommodate its geographically dispersed investor base and support cross-border corporate governance.
More about Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a pharmaceutical company incorporated in the People’s Republic of China. The company has dual-listed share classes, with A shares traded in China and S shares held in Singapore, and it operates across both markets, reflecting a cross-border shareholder base and governance framework.
For an in-depth examination of 2TZ stock, go to TipRanks’ Overview page.